NASDAQ
21.07.26 | 17:15
3,400 US-Dollar
+2,10 % +0,070
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| 26.06. | What's Going On With IceCure Medical Stock On Friday? | 6 | Benzinga.com | ||
| 25.06. | IceCure Medical: IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | 128 | PR Newswire | CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive... ► Artikel lesen | |
| 18.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.06. | IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance | 457 | PR Newswire | Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated... ► Artikel lesen | |
| 02.06. | IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance | 1 | Seeking Alpha | ||
| 02.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.06. | IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance | 355 | PR Newswire | Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy
CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical... ► Artikel lesen | |
| 19.05. | IceCure Medical: IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked | 241 | PR Newswire | At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors =3 cm and... ► Artikel lesen | |
| 13.05. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | IceCure Medical: IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement | 300 | PR Newswire | No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares
CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM)... ► Artikel lesen | |
| 12.05. | IceCure Medical GAAP EPS of $0.06, revenue of $911M | 3 | Seeking Alpha | ||
| 12.05. | IceCure Medical Ltd Q1 Sales Increase | 1 | RTTNews | ||
| 12.05. | IceCure Medical: IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America | 466 | PR Newswire | Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared... ► Artikel lesen | |
| 10.05. | Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag | 33 | Seeking Alpha | ||
| 06.05. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.04. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | IceCure Medical Ltd. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 26.03. | IceCure prices $4M direct offering, concurrent private placement | 2 | Seeking Alpha | ||
| 25.03. | IceCure Medical Reports Positive Trial Results For ProSense Cryoablation System | 2 | RTTNews |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,429 | -0,35 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| LIFEWARD | 7,550 | 0,00 % | Lifeward Ltd.: Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing | HUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| IMUNON | 1,790 | +15,48 % | Imunon, Inc.: IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer | Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance... ► Artikel lesen | |
| INSPIRE MEDICAL SYSTEMS | 45,200 | 0,00 % | Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance | First quarter revenue growth of 1.6%First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10First quarter operating cash flow of $12.8 million MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| INSPIREMD | 0,550 | 0,00 % | InspireMD Inc.: InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures | MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced... ► Artikel lesen | |
| GT BIOPHARMA | 0,347 | +1,70 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| MYOMO | 0,800 | +1,39 % | MYOMO, INC. - 8-K, Current Report | ||
| INOGEN | 5,550 | -2,63 % | Inogen appoints Andy Reding as chief operating officer | ||
| INTELLIGENT BIO SOLUTIONS | 1,910 | -3,05 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market | NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,215 | +0,16 % | Incannex Healthcare: Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea | MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 0,580 | -3,33 % | Lexaria Bioscience Corp.: Lexaria Updates Business Development | KELOWNA, BC / ACCESS Newswire / July 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to have experienced many... ► Artikel lesen | |
| GLUCOTRACK | 0,347 | -15,26 % | Glucotrack, Inc.; Lokahi Therapeutics: Glucotrack and Lokahi Therapeutics Complete Strategic Business Combination, Establishing Lokahi-Controlled Public Platform | RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lokahi Therapeutics... ► Artikel lesen | |
| LENSAR | 5,750 | 0,00 % | LENSAR, Inc.: LENSAR Reports First Quarter 2026 Results and Provides Business Update | 7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser... ► Artikel lesen | |
| HEARTBEAM | 0,598 | +5,17 % | HeartBeam receives patent for multi-modal cardiac sensing device | ||
| JIN MEDICAL INTERNATIONAL | 2,000 | +3,63 % | Jin Medical International Ltd. - 6-K, Report of foreign issuer |
Das Unternehmen ICECURE MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,10 % bei einem Aktienkurs von 3,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ICECURE MEDICAL LTD finden Sie auf Wallstreet Online.